Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market, By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia and Others), Type (Diagnosis and Treatment), Route of Administration (Oral, Parenteral and Others), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) – Industry Trends and Forecast to 2030.
Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market Analysis and Insights
The growing prevalence of infectious and respiratory diseases like COVID-19 and acute respiratory distress syndrome and the wide focus on vaccine developments and therapeutic and diagnostic products for these conditions have enhanced the market demand. The advancement in technology for easy supply of products and fast manufacturing facilities are also attributing to the growth of the market. The major market players are highly focused on product launches and approvals during this crucial period. In addition, the government and regulatory bodies are supporting market players with product approval due to surging emergence.
The Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market is supportive and aims to reduce the disease, thereby improving the recovery and performance of individuals. Data Bridge Market Research analyzes that Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market will grow at a CAGR of 9.9% during the forecast period of 2023 to 2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2020-2015) |
|
Quantitative Units |
Revenue in Million, Pricing in USD |
|
Segments Covered |
By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia and Others), Type (Diagnosis and Treatment), Route of Administration (Oral, Parenteral and Others), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) |
|
Country Covered |
U.S., Japan, China, Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Netherlands and the Rest of Europe |
|
Market Players Covered |
Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical, ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., and EUROSETS, among others |
Market Definition
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs. Most people who get ARDS are hospitalized for trauma or illness like COVID-19. The syndrome usually occurs when fluids build up in the lungs' tiny, elastic air sacs called alveoli. This fluid build-up causes less oxygen to reach the bloodstream. This deprives the organs of getting enough oxygen for their normal function. People with other illness develops ARDS within a few hours to days after the precipitating injury or infection. The risk of death increases with age, and depending on the severity of the illness, patients surviving the syndrome becomes hard. Severe illness or injury causing damage to the membrane sacs of the lungs leads to ARDS. The most common underlying causes for the said diseases include sepsis, inhalation of harmful substances, severe pneumonia, head, chest or another major injury, coronavirus disease 2019 (COVID-19) and others.
Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of these are discussed in detail below:
Drivers
- Increasing prevalence and incidence of acute lung injury
Patients with acute lung injuries are being widely reported due to numerous factors like the increasing aging population and the rising number of patients with sepsis and pneumonia. However, most people are diagnosed with lung injuries and acute respiratory distress syndrome only in the late stages. The said disease is a rapidly progressive condition occurring in patients with damaged lungs, causing bodily fluids to leak. The number of acute respiratory distress syndrome cases and lung injuries is increasing due to the emergence of various respiratory illness-causing viruses in recent years, like COVID-19.
Thereby, the incidence and prevalence of acute respiratory distress syndrome keep increasing. The disease has been widely recognized as a major clinical problem worldwide, carrying high morbidity and mortality burden. Hence, increasing prevalence and incident rates of acute lung injuries and accompanied acute respiratory distress syndrome is expected to drive the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market.
- Wide range of risk factors for Acute Respiratory Distress Syndrome (ARDS)
There is an enormous range of risk factors being reported for acute respiratory distress syndrome. There are environmental and individual risk factors involved with the syndrome. Patients with ARDS suffer from varying degrees of pulmonary artery vasoconstriction that cause the problem of getting enough oxygen into the blood. Thus, they usually need a ventilator to breathe. ARDS causes high mortality and ameliorates this deadly condition. Sepsis syndrome with multiple organ failure is the most common cause of death, while respiratory failure is second. Moreover, the severity of ARDS is associated significantly with the mortality rate among critically ill COVID-19 patients.
ARDS can be induced by multiple causes, including trauma. Risk factors for ARDS after multiple trauma include traumatic brain and chest injury, severity and duration of shock, number of transfused blood products, and infused crystalloids.
Opportunity
- Increasing awareness regarding acute respiratory distress syndrome (ARDS)
Since acute respiratory distress syndrome has multiple different causes, it is usually ignored under common causes of death. The requirement of advanced technical treatment and proper awareness of the condition can substantially decline acute respiratory distress syndrome incidence. As timely diagnosis and prevention are crucial to preventing or recovering faster, the public's attention is most important. Current governments and organizations have broadened the scope of lung injury research to include primary prevention of acute respiratory distress syndrome and reduce the morbidity or mortality rate for the syndrome.
The initiatives that started back are still aiding in the prevention of severe lung infections like ARDS and support biotechnology and pharmaceutical companies to innovate their research for new advancements in treatments. Though there is no proper or specific cure for ARDS, few associations are trying to increase awareness of the syndrome and aid patients in receiving timely healing for their lungs.
Such novel initiative programs and supportive care units started by various healthcare and lung care associations are increasing awareness among people regarding the cause and proper disease management on time. Thereby, increasing awareness regarding ARDS through diverse associations enhances the opportunity for future Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market growth.
Restraint/Challenge
- High cost of devices and treatments
Though acute respiratory distress syndrome is getting a wide range of advanced treatment options, the longer treatment cost is quite difficult for average-income people to afford. The utilization of critical care and intensive care unit services is increasing worldwide, and its expensive cost is a major concern in the current healthcare system. Patients with acute respiratory distress syndrome are commonly required to have long hospitalizations with frequent monetarization and ventilation usage, consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford a long-term stay get discharged in the initial stages of treatment. However, this increases the possibilities and susceptibilities for new complications in infections, which demands additional healthcare resources and treatment.
Post-COVID-19 Impact on Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market
COVID-19 has positively affected the market's growth as there is a rise in the demand for acute respiratory distress syndrome in the region. During the phase of COVID-19, it was indicated that several cases are asymptomatic, while 20% of COVID-19 cases follow a severe course, necessitating hospitalization. Severe cases of COVID-19 disease will ultimately lead to ARDS and pneumonia. This has been proven to be fatal for infected individuals. As ARDS shows the lung defect by damaging the alveoli, which are tiny air sacs in the lungs, the same level of defect has been observed in COVID-19 patients. This leads to a sudden influx of liquid, causing pneumonia. Hence COVID-19 has positively impacted this market.
Recent Developments
- In May 2021, Medtronic launched the SonarMed airway monitoring system. The system utilizes acoustic technology to check for endotracheal tube obstruction. This has helped the company to increase its product portfolio
- In July 2020, F. Hoffman-La Roche Ltd launched SARS-CoV-2 rapid antibody test. The test was launched in partnership with SD Biosenseor, Inc. This has helped the company to increase its product portfolio
Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market Scope
Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is categorized into five segments based on cause, type, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Cause
- Coronavirus Disease 2019 (COVID-19)
- Sepsis
- Inhalation Of Harmful Substances
- Severe Pneumonia
- Others
Based on the cause, the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is segmented into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia, and others.
Type
- Diagnosis
- Treatment
Based on type, the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is segmented into diagnosis and treatment.
Route of Administration
- Oral
- Parenteral
- Others
Based on route of administration, the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is segmented into oral, parenteral, and others.
End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Based on end user, the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is segmented into hospitals, specialty clinics, home healthcare and others.
Distribution Channel
- Direct Tender
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Based on distribution channel, the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is segmented into direct tender, hospital pharmacy, retail pharmacy and online pharmacy.
Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market Country Analysis/Insights
Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market is analyzed, and market size insights and trends are provided by the cause, type, route of administration, end user, and distribution channel as referenced above.
The country covered in the Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market are U.S., Japan, China, Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Netherlands and the Rest of Europe.
U.S. acute respiratory distress syndrome (ARDS) market is expected to grow due to an increase in the prevalence of acute lung injuries as well as a rise in the number of the patient pool of COVID-19 with ARDS. These are the key contributing factors which is expected to boost the growth of the market in the country.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market Share Analysis
Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market competitive landscape provides details of the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the company's focus on the Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market.
Some of the major players operating in the market are Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical, ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., and EUROSETS, among others.
SKU-
